Trial · NCT07891793
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Mature (MII) Oocytes Retrieved per Initiated Stimulation Cycle | From initiation of ovarian stimulation through oocyte retrieval, up to 14 days. | The number of mature metaphase II (MII) oocytes obtained following ovarian stimulation, assessed at the time of oocyte retrieval. The outcome will be expressed as the number of MII oocytes per initiated stimulation cycle. Participants whose cycles are cancelled before oocyte retrieval or who have no mature oocytes retrieved will be assigned a value of zero. |
| Secondary | Total Number of Oocytes Retrieved per Initiated Stimulation Cycle | From initiation of ovarian stimulation through oocyte retrieval, up to 14 days. | The total number of oocytes obtained during transvaginal oocyte retrieval. The outcome will be expressed as the number of retrieved oocytes per initiated stimulation cycle. Participants whose cycles are cancelled before oocyte retrieval or who have no oocytes retrieved will be assigned a value of zero. |
| Secondary | Oocyte maturation rate | At oocyte retrieval, up to 14 days after initiation of ovarian stimulation. | The percentage of retrieved oocytes classified as mature metaphase II (MII) oocytes. The maturation rate will be calculated as the number of MII oocytes divided by the total number of retrieved oocytes, multiplied by 100. The analysis will include participants with at least one retrieved oocyte. |
| Secondary | Normal fertilization rate (2PN) | At fertilization assessment, 1 day after ICSI. | The percentage of injected mature oocytes demonstrating normal fertilization, defined by the presence of two pronuclei (2PN) following intracytoplasmic sperm injection (ICSI). The fertilization rate will be calculated as the number of normally fertilized (2PN) oocytes divided by the total number of injected MII oocytes, multiplied by 100. |
| Secondary | Blastocyst formation rate | From fertilization through day 6 of embryo culture. | The percentage of normally fertilized (2PN) embryos developing into blastocysts by day 6 of embryo culture. The blastocyst formation rate will be calculated as the total number of blastocysts formed by day 6 divided by the number of normally fertilized (2PN) oocytes, multiplied by 100. |
| Secondary | Number of Usable Blastocysts per Oocyte Retrieval | From fertilization through day 6 of embryo culture. | The total number of blastocysts considered suitable for embryo transfer or cryopreservation according to predefined laboratory morphological assessment criteria. Blastocysts will be assessed on days 5 and 6 of embryo culture. |
| Secondary | Total Supplementary Gonadotropin Consumption | From initiation of ovarian stimulation through ovulation triggering or cycle cancellation, up to 14 days. | The cumulative dose of supplementary human menopausal gonadotropin (hMG) administered during ovarian stimulation, expressed in International Units (IU). Supplementary hMG may be administered at a dose of 150 IU daily from cycle day 8 according to predefined hormonal and ultrasonographic response criteria. Participants who do not require supplementary hMG will be assigned a value of zero. The initial administration of 150 μg corifollitropin alfa will not be included in the calculation of supplementary hMG consumption. |
| Secondary | Clinical Pregnancy Rate per Embryo Transfer | From oocyte retrieval through clinical pregnancy assessment, up to 9 months. | The percentage of embryo transfer procedures resulting in clinical pregnancy. Clinical pregnancy is defined as ultrasonographic confirmation of at least one intrauterine gestational sac with fetal cardiac activity. All fresh and frozen embryo transfers involving embryos derived from the study stimulation cycle and performed within 6 months after oocyte retrieval will be included. The clinical pregnancy rate will be calculated as the number of embryo transfer procedures resulting in clinical pregnancy divided by the total number of embryo transfer procedures performed within the specified follow-up period, multiplied by 100. |
| Secondary | Ongoing Pregnancy Rate per Embryo Transfer | From oocyte retrieval through ongoing pregnancy assessment, up to 10 months. | The percentage of embryo transfer procedures resulting in an ongoing pregnancy. Ongoing pregnancy is defined as the presence of a viable intrauterine pregnancy with fetal cardiac activity at 12 completed weeks of gestation. All fresh and frozen embryo transfers involving embryos derived from the study stimulation cycle and performed within 6 months after oocyte retrieval will be included. The ongoing pregnancy rate will be calculated as the number of embryo transfer procedures resulting in ongoing pregnancy divided by the total number of embryo transfer procedures performed within the specified follow-up period, multiplied by 100. |
| Secondary | Live Birth Rate per Embryo Transfer | From oocyte retrieval through delivery, up to 18 months. | The percentage of embryo transfer procedures resulting in the delivery of at least one live-born infant. Live birth is defined as the complete expulsion or extraction of a fetus from the mother, irrespective of gestational age, showing evidence of life after birth. All fresh and frozen embryo transfers involving embryos derived from the study stimulation cycle and performed within 6 months after oocyte retrieval will be included. Multiple live-born infants resulting from a single embryo transfer procedure will be counted as one live birth event. The live birth rate will be calculated as the number of embryo transfer procedures resulting in at least one live birth divided by the total number of embryo transfer procedures performed within the specified follow-up period, multiplied by 100. |
| Secondary | Single-Injection Completion Rate (SICR) | From initiation of ovarian stimulation through ovulation triggering or cycle cancellation, up to 14 days. | The percentage of participants completing ovarian stimulation using a single subcutaneous injection of 150 μg corifollitropin alfa without requiring supplementary gonadotropin administration. Successful single-injection completion is defined as reaching ovulation triggering without supplementary hMG or other gonadotropin administration. The rate will be calculated as the number of participants achieving single-injection completion divided by the total number of participants who initiated ovarian stimulation, multiplied by 100. |
| Secondary | Requirement for Supplementary hMG Administration | From initiation of ovarian stimulation through ovulation triggering or cycle cancellation, up to 14 days. | The percentage of participants requiring supplementary human menopausal gonadotropin (hMG) following the initial administration of 150 μg corifollitropin alfa. Supplementary hMG is administered from cycle day 8 when predefined hormonal and ultrasonographic criteria for continuation without additional gonadotropins are not fulfilled. The rate will be calculated as the number of participants receiving at least one supplementary hMG injection divided by the total number of participants who initiated ovarian stimulation, multiplied by 100. |
| Secondary | Cumulative Live Birth Rate per Initiated Stimulation Cycle | From initiation of ovarian stimulation through delivery, up to 18 months. | The percentage of initiated ovarian stimulation cycles resulting in at least one live birth following the transfer of embryos derived from the corresponding stimulation cycle. All fresh and frozen embryo transfers performed within 6 months after oocyte retrieval will be included. Each initiated stimulation cycle will be counted only once, regardless of the number of embryo transfers performed or the number of live-born infants. The cumulative live birth rate will be calculated as the number of initiated stimulation cycles resulting in at least one live birth divided by the total number of initiated stimulation cycles, multiplied by 100. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07891793/registered